Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD).
Alzheimer’s disease
Epidemiology
Symptomatic treatment
Treatment patterns
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
14
03
2023
accepted:
23
10
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries. The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.S. health plan [US] and UK-Clinical Practice Research Datalink [CPRD GOLD]). This analysis included patients with newly diagnosed AD dementia in 2018-2019, who initiated symptomatic AD drug therapy, with ≥ 1 year baseline period and ≥ 1 year of follow-up. Over median follow-ups of 698 and 645 days, 63% and 65% of AD dementia patients used symptomatic treatments, with 34% and 77% newly initiating therapy, constituting analytic samples of 7637 patients in the US database and 4470 patients in the CPRD, respectively. The median time to the first therapy was 14 days for US and 49 days for CPRD; donepezil ranked the as most frequently used (69% vs 61%), followed by memantine (19% vs 28%) in the US database and CPRD, respectively. Median time on first therapy was 213 and 334 days, and 30% and 12% of patients proceeded to a second treatment in the US and CPRD databases, respectively. Approximately two thirds of newly diagnosed AD dementia patients utilized approved symptomatic treatment. Time on first therapy was relatively short (< 1 year) and the majority did not move to a second therapy, highlighting the need for better adherence and persistence to existing AD symptomatic therapies and the need for additional therapies to alleviate the significant burden of AD dementia.
Sections du résumé
BACKGROUND
BACKGROUND
Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries.
METHODS
METHODS
The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.S. health plan [US] and UK-Clinical Practice Research Datalink [CPRD GOLD]). This analysis included patients with newly diagnosed AD dementia in 2018-2019, who initiated symptomatic AD drug therapy, with ≥ 1 year baseline period and ≥ 1 year of follow-up.
RESULTS
RESULTS
Over median follow-ups of 698 and 645 days, 63% and 65% of AD dementia patients used symptomatic treatments, with 34% and 77% newly initiating therapy, constituting analytic samples of 7637 patients in the US database and 4470 patients in the CPRD, respectively. The median time to the first therapy was 14 days for US and 49 days for CPRD; donepezil ranked the as most frequently used (69% vs 61%), followed by memantine (19% vs 28%) in the US database and CPRD, respectively. Median time on first therapy was 213 and 334 days, and 30% and 12% of patients proceeded to a second treatment in the US and CPRD databases, respectively.
CONCLUSION
CONCLUSIONS
Approximately two thirds of newly diagnosed AD dementia patients utilized approved symptomatic treatment. Time on first therapy was relatively short (< 1 year) and the majority did not move to a second therapy, highlighting the need for better adherence and persistence to existing AD symptomatic therapies and the need for additional therapies to alleviate the significant burden of AD dementia.
Identifiants
pubmed: 37946118
doi: 10.1186/s12883-023-03447-5
pii: 10.1186/s12883-023-03447-5
pmc: PMC10634008
doi:
Substances chimiques
Piperidines
0
Indans
0
Donepezil
8SSC91326P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
400Informations de copyright
© 2023. The Author(s).
Références
Alzheimers Dement. 2013 Nov;9(6):733-40
pubmed: 23332671
Dementia (London). 2016 Sep;15(5):1141-57
pubmed: 25370075
J Cent Nerv Syst Dis. 2020 Feb 29;12:1179573520907397
pubmed: 32165850
Semin Neurol. 2019 Apr;39(2):227-240
pubmed: 30925615
Drugs Aging. 2015 Jul;32(7):537-47
pubmed: 26033268
J Alzheimers Dis. 2020;76(2):579-589
pubmed: 32538845
Soc Psychiatry Psychiatr Epidemiol. 2021 Mar;56(3):409-416
pubmed: 32494994
Front Neurosci. 2021 Oct 08;15:749305
pubmed: 34690684
Alzheimers Dement. 2019 Jul;15(7):888-898
pubmed: 31164314
Alzheimers Dement. 2019 Jan;15(1):17-24
pubmed: 30243772
AMIA Annu Symp Proc. 2021 Jan 25;2020:393-401
pubmed: 33936412
J Gen Intern Med. 2021 May;36(5):1371-1379
pubmed: 33537953
J Clin Anesth. 2016 Sep;33:315-6
pubmed: 27555184
Int J Geriatr Psychiatry. 2018 Dec;33(12):1562-1581
pubmed: 30270451
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
J Int Med Res. 2006 Jul-Aug;34(4):339-47
pubmed: 16989488
Curr Med Res Opin. 2002;18(3):129-38
pubmed: 12094822
Neurol Ther. 2017 Jun;6(1):131-144
pubmed: 28508250
Am J Psychiatry. 2007 Dec;164(12 Suppl):5-56
pubmed: 18340692
Am J Epidemiol. 2022 Jul 23;191(8):1347-1351
pubmed: 35388413
Alzheimers Dement (N Y). 2020 Apr 29;6(1):e12014
pubmed: 32355871
J Am Geriatr Soc. 2018 Jan;66(1):170-178
pubmed: 29131306
J Prev Alzheimers Dis. 2023;10(3):362-377
pubmed: 37357276
Alzheimers Dement. 2023 Apr;19(4):1598-1695
pubmed: 36918389
Anesth Analg. 1996 Aug;83(2):320-4
pubmed: 8694312
Age Ageing. 2019 Sep 1;48(5):711-718
pubmed: 31081513